FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1996676489> ?p ?o ?g. }

• W1996676489 endingPage "860" @default.
• W1996676489 startingPage "849" @default.
• W1996676489 abstract "The injectable adipocytolytic drug ATX-101 is the first nonsurgical treatment for the reduction of submental fat (SMF) to undergo comprehensive clinical evaluation. This study aimed to confirm the efficacy and safety of ATX-101 for SMF reduction through a post hoc pooled analysis of two large phase 3 studies.Patients with unwanted SMF were randomized to receive 1 or 2 mg/cm(2) of ATX-101 or a placebo injected into their SMF during a maximum of four treatment sessions spaced approximately 28 days apart, with a 12-week follow-up period. The proportions of patients with reductions in SMF of one point or more on the Clinician-Reported SMF Rating Scale (CR-SMFRS) and the proportions of patients satisfied with the appearance of their face and chin [Subject Self-Rating Scale (SSRS) score ≥4] were reported overall and in subgroups. Other efficacy measures included improvements in the Patient-Reported SMF Rating Scale (PR-SMFRS), calliper measurements of SMF thickness, and assessment of skin laxity [Skin Laxity Rating Scale (SLRS)]. Adverse events and laboratory test results were recorded.Significantly greater proportions of the patients had improvements in clinician-reported measures (≥1-point improvement in CR-SMFRS: 58.8 and 63.8 % of the patients who received ATX-101 1 and 2 mg/cm(2), respectively, and 28.6 % of the placebo recipients; p < 0.001 for both ATX-101 doses vs. placebo) and patient-reported measures (≥1-point improvement in PR-SMFRS: 60.0 and 63.1 % of the patients who received ATX-101 1 and 2 mg/cm(2), respectively, vs. 34.3 % of the placebo recipients; p < 0.001 for both), analyzed alone or in combination, with ATX-101 versus placebo. These improvements correlated moderately with patient satisfaction regarding face and chin appearance (SSRS score ≥4: 60.8 and 65.4 % of the patients who received ATX-101 1 and 2 mg/cm(2), respectively, vs. 29.0 % of the placebo recipients; p < 0.001 for both). In this study, ATX-101 was effective irrespective of gender, age, or body mass index. Reduction in SMF with ATX-101 was confirmed by calliper measurements (p < 0.001 for both doses vs. placebo) and generally did not lead to worsening of skin laxity (SLRS improved or was unchanged: 91.3 and 90.5 % of the patients who received ATX-101 1 and 2 mg/cm(2), respectively, and 91.6 % of the placebo recipients). Adverse events were mostly transient, mild to moderate in intensity, and localized to the treatment area.The findings show ATX-101 to be an effective and well-tolerated pharmacologic treatment for SMF reduction." @default.
• W1996676489 created "2016-06-24" @default.
• W1996676489 creator A5001877297 @default.
• W1996676489 creator A5046928489 @default.
• W1996676489 creator A5046981674 @default.
• W1996676489 creator A5047715707 @default.
• W1996676489 creator A5071670058 @default.
• W1996676489 creator A5078294597 @default.
• W1996676489 date "2014-07-02" @default.
• W1996676489 modified "2023-10-11" @default.
• W1996676489 title "Results from a Pooled Analysis of Two European, Randomized, Placebo-Controlled, Phase 3 Studies of ATX-101 for the Pharmacologic Reduction of Excess Submental Fat" @default.
• W1996676489 cites W1979251046 @default.
• W1996676489 cites W2015198715 @default.
• W1996676489 cites W2018283960 @default.
• W1996676489 cites W2024638759 @default.
• W1996676489 cites W2025347076 @default.
• W1996676489 cites W2030325667 @default.
• W1996676489 cites W2033794165 @default.
• W1996676489 cites W2049098620 @default.
• W1996676489 cites W2055207821 @default.
• W1996676489 cites W2057117393 @default.
• W1996676489 cites W2092043932 @default.
• W1996676489 cites W2096767171 @default.
• W1996676489 cites W2119853482 @default.
• W1996676489 cites W2131564003 @default.
• W1996676489 cites W2136629613 @default.
• W1996676489 cites W2137733966 @default.
• W1996676489 cites W2140068483 @default.
• W1996676489 cites W2146251994 @default.
• W1996676489 cites W2153623401 @default.
• W1996676489 cites W2153631304 @default.
• W1996676489 cites W4206596305 @default.
• W1996676489 cites W4248019641 @default.
• W1996676489 doi "https://doi.org/10.1007/s00266-014-0364-9" @default.
• W1996676489 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4175004" @default.
• W1996676489 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24984785" @default.
• W1996676489 hasPublicationYear "2014" @default.
• W1996676489 type Work @default.
• W1996676489 sameAs 1996676489 @default.
• W1996676489 citedByCount "43" @default.
• W1996676489 countsByYear W19966764892015 @default.
• W1996676489 countsByYear W19966764892016 @default.
• W1996676489 countsByYear W19966764892017 @default.
• W1996676489 countsByYear W19966764892018 @default.
• W1996676489 countsByYear W19966764892019 @default.
• W1996676489 countsByYear W19966764892020 @default.
• W1996676489 countsByYear W19966764892021 @default.
• W1996676489 countsByYear W19966764892022 @default.
• W1996676489 countsByYear W19966764892023 @default.
• W1996676489 crossrefType "journal-article" @default.
• W1996676489 hasAuthorship W1996676489A5001877297 @default.
• W1996676489 hasAuthorship W1996676489A5046928489 @default.
• W1996676489 hasAuthorship W1996676489A5046981674 @default.
• W1996676489 hasAuthorship W1996676489A5047715707 @default.
• W1996676489 hasAuthorship W1996676489A5071670058 @default.
• W1996676489 hasAuthorship W1996676489A5078294597 @default.
• W1996676489 hasBestOaLocation W19966764891 @default.
• W1996676489 hasConcept C108516343 @default.
• W1996676489 hasConcept C126322002 @default.
• W1996676489 hasConcept C138496976 @default.
• W1996676489 hasConcept C141071460 @default.
• W1996676489 hasConcept C142724271 @default.
• W1996676489 hasConcept C15744967 @default.
• W1996676489 hasConcept C168563851 @default.
• W1996676489 hasConcept C197934379 @default.
• W1996676489 hasConcept C203092338 @default.
• W1996676489 hasConcept C204787440 @default.
• W1996676489 hasConcept C27081682 @default.
• W1996676489 hasConcept C67761136 @default.
• W1996676489 hasConcept C71924100 @default.
• W1996676489 hasConcept C83849319 @default.
• W1996676489 hasConceptScore W1996676489C108516343 @default.
• W1996676489 hasConceptScore W1996676489C126322002 @default.
• W1996676489 hasConceptScore W1996676489C138496976 @default.
• W1996676489 hasConceptScore W1996676489C141071460 @default.
• W1996676489 hasConceptScore W1996676489C142724271 @default.
• W1996676489 hasConceptScore W1996676489C15744967 @default.
• W1996676489 hasConceptScore W1996676489C168563851 @default.
• W1996676489 hasConceptScore W1996676489C197934379 @default.
• W1996676489 hasConceptScore W1996676489C203092338 @default.
• W1996676489 hasConceptScore W1996676489C204787440 @default.
• W1996676489 hasConceptScore W1996676489C27081682 @default.
• W1996676489 hasConceptScore W1996676489C67761136 @default.
• W1996676489 hasConceptScore W1996676489C71924100 @default.
• W1996676489 hasConceptScore W1996676489C83849319 @default.
• W1996676489 hasIssue "5" @default.
• W1996676489 hasLocation W19966764891 @default.
• W1996676489 hasLocation W19966764892 @default.
• W1996676489 hasLocation W19966764893 @default.
• W1996676489 hasLocation W19966764894 @default.
• W1996676489 hasOpenAccess W1996676489 @default.
• W1996676489 hasPrimaryLocation W19966764891 @default.
• W1996676489 hasRelatedWork W2047125649 @default.
• W1996676489 hasRelatedWork W2559795988 @default.
• W1996676489 hasRelatedWork W2766008196 @default.
• W1996676489 hasRelatedWork W3155195005 @default.
• W1996676489 hasRelatedWork W3172359983 @default.
• W1996676489 hasRelatedWork W3212096909 @default.

• next